Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor
To the Editor.—Montelukast (MK-0476) is an orally administered, specific cysteinyl leukotriene receptor antagonist now with labeling approved by the Food and Drug Administration for the treatment of asthma. The study by Dr Knorr and colleagues1 reported that montelukast improved morning forced expiratory volume in 1 second in 6- to 14-year-old children with chronic asthma. The most common adverse experiences were headache, asthma, and upper respiratory tract infection. However, the authors also reported an increase in fever (7.5% with montelukast vs 3.7% with placebo) and influenza (8.5% with montelukast vs 4.4% with placebo) and a decrease in abdominal pain (5% with montelukast vs 10.4% with placebo).
Lawyer C. Montelukast for Children With Asthma. JAMA. 1998;280(11):967. doi:10-1001/pubs.JAMA-ISSN-0098-7484-280-11-jbk0916